NGS Dystonia Panel: Comprehensive Genetic Test in Dubai, UAE | 2,600 AED

Executive Summary & Core Metrics

Executive Summary & Core Metrics: This NGS Dystonia Panel delivers 99.9% diagnostic sensitivity using targeted next-generation sequencing with Sanger confirmation, processed in an ISO 9001:2015 certified laboratory. Home blood collection is available daily from 8 AM to 11 PM via DHA-compliant cold-chain logistics. Every result includes a post-test telephonic consultation with a Consultant Medical Genetics specialist to ensure accurate clinical interpretation. Direct insurance verification is available via WhatsApp at +971 54 548 8731.

✓

99.9% Diagnostic SensitivityISO 9001:2015 Certified Lab | Sanger validation

✓

Home Collection (8 AM – 11 PM)Cold-chain, DHA-compliant logistics across Dubai

✓

Post-Test Tele-GuidanceClinical interpretation by Consultant Medical Genetics

Test Overview & Methodology

The NGS Dystonia Panel uses targeted next-generation sequencing to analyze more than 40 genes associated with hereditary dystonia, a neurological movement disorder characterized by sustained or intermittent muscle contractions. This single-test approach replaces the need for sequential single-gene analysis, delivering a comprehensive genetic diagnosis with 99.9% sensitivity through orthogonal Sanger confirmation of all clinically significant variants.

Feature	Our Test (NGS Dystonia Panel)	Closest Alternative (Single-Gene Sequencing)
Precision	99.9% diagnostic sensitivity with Sanger confirmation	~60–70% for restricted gene sets
Method	Targeted NGS with orthogonal Sanger confirmation	Sanger sequencing for single or few genes
Turnaround Time	40 working days	30–45 working days per gene; multiple rounds often required
Comprehensiveness	More than 40 dystonia-associated genes in one test	1–5 genes per request

Physician Insight & Safety Protocols

Clinical Note from Dr. Lina Osama Zaki Quteineh (DHA Registration ID: 9294403, Consultant Medical Genetics):
This NGS panel provides robust molecular data, yet a genetic result represents only one component of the diagnostic pathway. Correlation with a comprehensive neurological examination, detailed family history, and phenotypic assessment is essential to avoid misinterpretation. I strongly advise every patient to review their findings with a specialist who understands the full clinical spectrum of dystonia. The molecular diagnosis must always be contextualised within the broader clinical picture.

Advisory Medication Caution

⛔ Medication Safety Warning

Do not discontinue or adjust any prescribed medication without direct consultation with your treating physician. Genetic test results do not override current anti-dystonic or anticholinergic therapy. Abrupt cessation of these medications can provoke severe dystonic crisis, respiratory compromise, or loss of airway protection. Always involve your neurologist before making any changes to your treatment regimen.

Exclusion Criteria & Emergency Indicators

Safety Exclusion Criteria & Emergency Red Flags

Exclusion: This test is not validated for prenatal diagnosis. Informed consent must be obtained from a legal guardian for minors, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Exclusion: Whole blood volume of less than 5 mL, or samples that have been frozen, cannot be processed and will require recollection.
Emergency Red Flag: Seek immediate emergency medical care if you develop acute laryngeal dystonia, breathing difficulty, severe generalised rigidity, or any sign of compromised airway patency.

Patient FAQ & Clinical Guidance

1. What exactly does this NGS dystonia test detect?

This NGS dystonia panel identifies harmful genetic variants in more than 40 genes known to cause hereditary dystonia. The results guide precise personalized treatment planning and enable accurate genetic counseling for at-risk family members.

2. How is the blood sample collected at home?

A hospital-grade phlebotomist visits your home between 8 AM and 11 PM to collect 10 mL of blood from a peripheral vein. The sample is immediately placed in a temperature-controlled transport system and delivered to our ISO 9001:2015 certified laboratory under continuous cold-chain monitoring.

3. When will I receive my test results?

Your results are securely delivered within 40 working days from sample receipt. You will also receive a scheduled telephonic consultation with a Consultant Medical Genetics specialist to interpret the findings and discuss clinical implications.

4. Can this test replace a neurological examination?

No. This genetic test is an adjunctive diagnostic tool and must be interpreted alongside a thorough neurological examination, family history, and clinical phenotyping. The genetic result alone is not sufficient for diagnosis or treatment decisions.

5. Is the test covered by health insurance in Dubai?

Coverage varies by insurance provider and policy. You can verify your insurance coverage directly by sending a WhatsApp message to +971 54 548 8731. Our team will coordinate with your insurer to determine eligibility and any applicable co-payments.

UAE Regulatory & Data Privacy Adherence

Data Protection Compliance: DNA Labs UAE operates under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted during transit and at rest, with access restricted to authorised clinical personnel only. Your results are never shared with third parties without explicit written consent.

Clinical Safety & Consent Compliance: This test adheres to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that informed consent is obtained prior to sample collection and that all diagnostic procedures meet stringent UAE healthcare quality standards.

Clinical & Logistical Metadata

Attribute	Detail
Test Name	NGS Dystonia Panel (Targeted Next-Generation Sequencing with Sanger Confirmation)
Price (AED)	2,600 AED
Turnaround Time	40 working days
Sample Type / Matrix	Whole blood (EDTA), 5–10 mL minimum
Methodology Used	Targeted NGS with orthogonal Sanger confirmation
ICD-10-CM Code	G24.9 (Dystonia, unspecified)
LOINC Code	94277-6 (Movement disorder gene panel)
DHA Facility License & Laboratory Address Invariants	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE